While Lilly’s position in the obesity market and wider GLP-1 space has remained largely unshakeable in recent months, a crack in the company’s armor may be forming, according to at least one analyst.

Hong Kong-listed Insilico Medicine has reached a deal with U.S. pharma giant Eli Lilly for AI-discovered drugs. The two companies have worked together since 2023. Insilico's CEO, Alex Zhavoronkov, ...

Eli Lilly scored $408 million in U.S. sales of eczema treatment Ebglyss in its first full year on the market in 2025. Now, with positive results from a phase 3 trial of the IL-13 inhibitor, the ...

Several pharmaceutical companies have recently posted encouraging clinical data for their weight-loss candidates. However, most of these won't be approved soon, and Eli Lilly has strong programs of ...

Eli Lilly’s LLY-2.09%decrease; red down pointing triangle experimental weight-loss drug retatrutide met the primary and key secondary endpoints in a trial, showing significant improvements in weight ...

In a surprising move, Eli Lilly’s stock has been downgraded by HSBC analysts who argue that the heavily hyped weight-loss-drug market is due for a correction — and that the middle-class Americans who ...

With shares up 20% over the past 12 months, Eli Lilly appears to have come out on top in the battle to dominate the weight-loss drug market, with rival Novo Nordisk sinking 52% over the same period.

Matthew Herper covers medical innovation — both its promise and its perils. Everything changed with a white envelope. On Dec. 20, 2018, Jacob Van Naarden, the chief operating officer of a biotech ...

This is read by an automated voice. Please report any issues or inconsistencies here. “Southern Hospitality” star Grace Lilly was arrested Tuesday in South Carolina on suspicion of drug possession ...

Eli Lilly's growth rate has accelerated significantly in recent years due to its GLP-1 drugs. The stock, however, trades at more than 40 times its trailing earnings. Eli Lilly (NYSE: LLY) has been an ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Want to stay on top of ...

With the success of GLP-1-based drugs, pharmaceutical companies are aggressively pursuing next-generation versions that could provide patients with more refined options for controlling diabetes and ...